These two reliable and high-yielding dividend payers from the healthcare sector should be on your buy list today.

MRK scores an A+ grade for Profitability, aided by high gross and EBITDA margins of 78% and 46%, respectively. Moreover, it ...

Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announces it has received positive and ...

Thousands of Medicare recipients will face higher costs for expensive cancer drugs following passage of two provisions in the One Big Beautiful Bill Act, signed by President Donald Trump in July, The ...

President Trump escalated pressure on the pharmaceutical industry last week by sending letters to 17 major drug companies ...

Facing an end to Keytruda's market exclusivity, the company will cut $3 billion in costs that it plans to redeploy in support ...

Merck is slashing $3 billion from its annual spending as it braces for off-brand competition to its cancer drug Keytruda, the ...

Merck (NYSE:MRK) is cutting $3 billion from its annual expenses as it prepares for generic competition to its blockbuster ...

The approval introduces the first perioperative anti-PD-1 treatment regimen for adults with resectable locally advanced head and neck squamous cell carcinoma.

Alvotech and Dr. Reddy’s have entered into a collaboration and license agreement to co-develop, manufacture and commercialize a biosimilar candidate to Merck Sharp & Dohme’s Keytruda ...